地拉罗司去哪买的到呢？

(Deferasirox) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use. Its chemical name is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. So, where can I buy Deferasirox?

Deferasirox (Deferasirox) is already on the market in China. Domestic patients can buy it at major domestic hospitals or pharmacies with prescriptions issued by doctors. However, the price of Deferasirox (Deferasirox) is relatively high after it is launched in China. 

Fortunately, there are also foreign versions for everyone to choose from. Deferasirox (Deferasirox) imported from Switzerland by Novartis to India has a specification of 400mg*30 tablets/box and a price of about $700. 

The specification of Deferasirox produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the floating exchange rate, the price will be different. Please consult the medical companion for the specific price! 

If necessary, patients can obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), which are guaranteed to be genuine.

Deferasirox dispersible tablets should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Deferasirox dispersible tablets should not be taken together with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet.

Completely dissolve Deferasirox tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining drug must be added to a small amount of water, apple juice or orange juice and mixed well before taking it. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Deferasirox was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for Deferasirox (Deferasirox) for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

The above is the content of the purchase channels of Deferasirox, I hope it can help you!